Treatment of Myasthenia Gravis by Preventing Acetylcholine Receptor Modulation

@article{Losen2008TreatmentOM,
  title={Treatment of Myasthenia Gravis by Preventing Acetylcholine Receptor Modulation},
  author={Mario Losen and Pilar Martinez-Martinez and Marko Phernambucq and Janine Schuurman and Paul W.H.I. Parren and Marc H. de Baets},
  journal={Annals of the New York Academy of Sciences},
  year={2008},
  volume={1132}
}
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies mainly directed to the acetylcholine receptor (AChR) of the neuromuscular junction. Induction of antigenic modulation and complement activation by such autoantibodies leads to ultrastructural damage of the postsynaptic membrane and loss of AChR and associated proteins. Reduction of antigenic modulation by increasing the expression of the receptor‐associated anchor protein, rapsyn, or by functionally monovalent competing IgG4… Expand
Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction
TLDR
Findings suggest that MuSK-MG may be different in etiological and pathological mechanisms from AChR-MG, and the effector functions of IgG subclasses on synapse structure and function are discussed in this review. Expand
Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4.
TLDR
Screening for auto-antibodies to different postsynaptic targets, and also for low-affinity antibodies, is contributing to a more accurate diagnosis of MG patients and to develop new, more antigen specific, therapies. Expand
Autoimmune myasthenia gravis
  • N. Gilhus
  • Medicine
  • Expert review of neurotherapeutics
  • 2009
TLDR
Until curative or antigen-specific therapy become available, the well-established treatment of myasthenia gravis gives good-to-excellent results in most patients, with acceptable quality of life and no increased mortality. Expand
The auto-antigen repertoire in myasthenia gravis
TLDR
The reported auto-antibodies in MG patients are comprehensively reviewed and their role in the pathology of this autoimmune disease is discussed. Expand
Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil
TLDR
The data suggest that MMF acts as a potent immunosuppressant drug in EAMG, and suppression of anti-rat AChR antibody titers correlated to an improvement of clinical outcome. Expand
Current and emerging therapies for the treatment of myasthenia gravis
TLDR
Study performed in the animal model of MG demonstrated that several more selective or antigen-specific approaches, ranging from mucosal tolerization to inhibition of complement activity or cellular therapy, might be feasible. Expand
Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys
TLDR
Results represent proof-of principle data for therapy of acetylcholine receptor-myasthenia gravis with a monovalent antibody format that blocks binding of pathogenic autoantibodies. Expand
Clinical and functional characteristics of seronegative and musk myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction (NMJ). Most patients have antibodies (Abs) against the acetylcholine receptor (AChR) or muscle specific kinase (MuSK)Expand
Characterization of thymic hyperplasia associated with autoimmune Myasthenia Gravis : role of the chemokines CXCL12 and CXCL13
TLDR
The results obtained in the course of this PhD showed that the abnormal development of SDF-1-expressing HEVs and the CXCL13 overexpression play a central role in the recruitment of peripheral cells to the MG thymus. Expand
Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.
TLDR
The results support an antigen driven immune response in the MG thymus, but the paucity of AChR-specific B cells, in combination with the observed polyclonal expansions suggest a more diverse immune response than expected. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 50 REFERENCES
Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice.
TLDR
It is found that immunization of mice with AChR leads to a twofold increase in the rate of junctional A ChR degradation, and the role of antigenic modulation as a major pathologic mechanism in MG is questioned. Expand
Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor
TLDR
Levels of anti-Torpedo AChR antibodies in serum measured by radioimmunoassay were lower in orally tolerant compared to control animals, and the model might have a relevance for studying the pathogenesis and immunotherapy of human myasthenia gravis. Expand
Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor
TLDR
Examination of the ability of bivalent F(ab')2 and monovalent Fab fragments of monoclonal antibody (mAb) 35 to passively transfer experimental autoimmune MG (EAMG) in rats provides evidence that antigenic modulation of endplate AChR is sufficient to generate passive transfer of EAMG and supports the pathogenic potential of the anti‐MIR antibodies in MG. Expand
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis
An acute phase of experimental autoimmune myasthenia gravis (EAMG) occurs transiently early in the immune response of Lewis rats to nicotinic acetylcholine receptors (AChR) when Bordetella pertussisExpand
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
TLDR
The results indicate the involvement of MuSK antibodies in the pathogenesis of AChR-Ab–seronegative MG, thus defining two immunologically distinct forms of the disease. Expand
Serum Globulin in Myasthenia Gravis: Inhibition of α-Bungarotoxin Binding to Acetylcholine Receptors
TLDR
Serum factors that inhibit the binding of 125I-labeled α-bungarotoxin to the acetylcholine receptor extracted in detergent from denervated rat muscle were detected by a sensitive assay and may help explain the involvement of the immune system in the pathophysiology of the neuromuscular junction in patients with myasthenia gravis. Expand
Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
TLDR
In EAMG rats, despite deposits of the membrane attack complex, the rapsyn-overexpressing muscles showed no decrement in the CMAPs, no loss of AChR, and the majority had normal postsynaptic folds, whereas endplates of untreated muscles showed typical A ChR loss and morphological damage, lending support to the hypothesis that individual differences in innate rappingyn expression could be a factor in determining disease severity. Expand
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
TLDR
The data suggest that the pathogenesis of myasthenia gravis often involves and antibody-mediated autoimmune attack on the acetylcholine receptors of the neuromuscular junction. Expand
EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS AND MYASTHENIA GRAVIS: BIOCHEMICAL AND IMMUNOCHEMICAL ASPECTS *
TLDR
The chronic phase of EAMG appears a good model of MG, since in both cases similar concentrations of 7-S immunoglobulin against determinants on muscle AChR other than the toxin binding site are found. Expand
Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis
TLDR
Data demonstrate that resistance of the AChR protein to antibody-mediated degradation is the primary mechanism that accounts for the resistance to passive transfer EAMG in aged rats. Expand
...
1
2
3
4
5
...